Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Myos Inc
Profile last edited on: 1/27/2021      CAGE: 822P9      UEI: JF5CJQH8NNH1

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2017
First Award
2018
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

99 Kneeland Street Unit 714
Boston, MA 02111
   (607) 215-6401
   N/A
   N/A
Location: Single
Congr. District: 07
County: Suffolk

Public Profile

Myos Inc was founded as an affiliate to the nonprofit Terry's Foundation for Muscular Dystrophy with a goal of advancing the commercialization effort of the nonprofit. With strong ties to Harvard University, the company's technology is centered around cell therapy and a method for programming smart cells to go into the body.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$709,023
Phase II Dollars
$0
Total Awarded
$709,023

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
0
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $259,487
Project Title: Translational development of recombinant protein therapeutic for LGMD2B
2019 1 NIH $224,811
Project Title: Optimizing Membrane Repair for the Treatment of Duchenne Muscular Dystrophy
2018 1 NIH $224,725
Project Title: Genome-Wide Crispr Screen to Identify Pro-Myogenic Factors for Cell Therapy of DMD
0 1 NIH $295,536
Project Title: Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy
0 1 NIH $275,651
Project Title: Translational development of novel CRISPR approach to treat genomic duplications

Key People / Management

  Richard Horgan -- Co-Founder

  Louis M Kunkel

  Monkol Lek

  Noah Weisleder -- Co-Founder and Scientific Advisor

Company News

Jun 22 2018
Inspired by family, a new Duchenne foundation and biotech launch in Boston